The Experts below are selected from a list of 828 Experts worldwide ranked by ideXlab platform
M J O'connell - One of the best experts on this subject based on the ideXlab platform.
-
Aggressive Chemotherapy in the Treatment of Burkitt's and Non-BurKitt's Undifferentiated Lymphoma
Leukemia & lymphoma, 1995Co-Authors: Joseph J. Mazza, M M Oken, J. D. Hines, Janet Andersen, Richard S. Neiman, Risa B. Mann, M J O'connellAbstract:Because of the aggressive nature and frequent recurrence of malignant Lymphomas of the Undifferentiated type, we used a multi-drug induction chemotherapy regimen that has met with some success in children with similar type of histopathology followed by intensification and 8 cycles of consolidation chemotherapy in an attempt to prolong the duration of remission and survival in adult patients with this diagnosis. Fifty-one patients (median age 35 years) with Undifferentiated malignant Lymphoma were collected over a 4 year period (1984-1988) and entered into a phase III protocol done under the auspices of the Eastern Cooperative Oncology Group (ECOG). Six patients who had their diagnosis made at surgery and had resection of their tumor were excluded from analysis of response to therapy. Sixty percent of the patients had Stage IV disease. Sixteen patients had marrow involvement and five had central nervous system (CNS) disease. None of the patients received CNS radiation therapy. The 45 patients evaluated for...
Bayard D. Clarkson - One of the best experts on this subject based on the ideXlab platform.
-
Small Non-Cleaved-Cell Lymphoma (Undifferentiated Lymphoma, Burkitt's Type) in American Adults: Results with Treatment Designed for Acute Lymphoblastic Leukemia
The American journal of medicine, 1991Co-Authors: David J. Straus, George Y. Wong, John Liu, Jill Oppenberg, Daniel A. Filippa, Jonathan W. M. Gold, Kenneth Offit, Bayard D. ClarksonAbstract:Abstract purpose: Small non-cleaved-cell Lymphoma (SNCL) "Burkitt's type," a rapidly growing Lymphoma, has been rare among adults in the United States, but has greatly increased in incidence with the acquired immunodeficiency syndrome epidemic. This report details the results of treatment of adult SNCL with a series of protocols originally designed for the treatment of acute lymphoblastic leukemia (ALL). patients and methods: Between July 1973 and May 1987, 29 adults with newly diagnosed SNCL were treated at Memorial Hospital with intensive chemotherapy originally designed for ALL: the cyclophosphamide L-2, L-10, L-17, and L-20 protocols. Nine patients had positive serologies for human immunodeficiency virus (HIV) infection. One patient with all measurable disease resected was not evaluable for response. results: Sixteen of 28 evaluable patients (57%) achieved a complete remission with treatment. With follow-up as long as 153 months (median, 47 months), 50% of all patients and 59% of patients with negative or unknown HIV serologies have survived and are probably cured. Patients with an initial serum lactic acid dehydrogenase (LDH) level of greater than 500 U/L had a significantly shortened survival as compared with those with a lower serum LDH. Other pretreatment patient characteristics associated with a shortened survival of borderline statistical significance were high National Cancer Institute stage (C, D) and bone marrow involvement. These results are similar to those for ALL and lymphoblastic Lymphoma and are comparable to those for American SNCL in the literature. conclusions: Approximately one half of adults with SNCL are curable with intensive chemotherapy. More intensive chemotherapy with hematopoietic growth factor and/or autologous bone marrow or peripheral stem cell support may increase curability.
Joseph J. Mazza - One of the best experts on this subject based on the ideXlab platform.
-
Aggressive Chemotherapy in the Treatment of Burkitt's and Non-BurKitt's Undifferentiated Lymphoma
Leukemia & lymphoma, 1995Co-Authors: Joseph J. Mazza, M M Oken, J. D. Hines, Janet Andersen, Richard S. Neiman, Risa B. Mann, M J O'connellAbstract:Because of the aggressive nature and frequent recurrence of malignant Lymphomas of the Undifferentiated type, we used a multi-drug induction chemotherapy regimen that has met with some success in children with similar type of histopathology followed by intensification and 8 cycles of consolidation chemotherapy in an attempt to prolong the duration of remission and survival in adult patients with this diagnosis. Fifty-one patients (median age 35 years) with Undifferentiated malignant Lymphoma were collected over a 4 year period (1984-1988) and entered into a phase III protocol done under the auspices of the Eastern Cooperative Oncology Group (ECOG). Six patients who had their diagnosis made at surgery and had resection of their tumor were excluded from analysis of response to therapy. Sixty percent of the patients had Stage IV disease. Sixteen patients had marrow involvement and five had central nervous system (CNS) disease. None of the patients received CNS radiation therapy. The 45 patients evaluated for...
David J. Straus - One of the best experts on this subject based on the ideXlab platform.
-
Small Non-Cleaved-Cell Lymphoma (Undifferentiated Lymphoma, Burkitt's Type) in American Adults: Results with Treatment Designed for Acute Lymphoblastic Leukemia
The American journal of medicine, 1991Co-Authors: David J. Straus, George Y. Wong, John Liu, Jill Oppenberg, Daniel A. Filippa, Jonathan W. M. Gold, Kenneth Offit, Bayard D. ClarksonAbstract:Abstract purpose: Small non-cleaved-cell Lymphoma (SNCL) "Burkitt's type," a rapidly growing Lymphoma, has been rare among adults in the United States, but has greatly increased in incidence with the acquired immunodeficiency syndrome epidemic. This report details the results of treatment of adult SNCL with a series of protocols originally designed for the treatment of acute lymphoblastic leukemia (ALL). patients and methods: Between July 1973 and May 1987, 29 adults with newly diagnosed SNCL were treated at Memorial Hospital with intensive chemotherapy originally designed for ALL: the cyclophosphamide L-2, L-10, L-17, and L-20 protocols. Nine patients had positive serologies for human immunodeficiency virus (HIV) infection. One patient with all measurable disease resected was not evaluable for response. results: Sixteen of 28 evaluable patients (57%) achieved a complete remission with treatment. With follow-up as long as 153 months (median, 47 months), 50% of all patients and 59% of patients with negative or unknown HIV serologies have survived and are probably cured. Patients with an initial serum lactic acid dehydrogenase (LDH) level of greater than 500 U/L had a significantly shortened survival as compared with those with a lower serum LDH. Other pretreatment patient characteristics associated with a shortened survival of borderline statistical significance were high National Cancer Institute stage (C, D) and bone marrow involvement. These results are similar to those for ALL and lymphoblastic Lymphoma and are comparable to those for American SNCL in the literature. conclusions: Approximately one half of adults with SNCL are curable with intensive chemotherapy. More intensive chemotherapy with hematopoietic growth factor and/or autologous bone marrow or peripheral stem cell support may increase curability.
Albert B. Deisseroth - One of the best experts on this subject based on the ideXlab platform.
-
Treated Cancer Patients
2016Co-Authors: V. Holohan, Paul I. Terasaki, Albert B. DeisserothAbstract:A retrospective review of HIA antibody testing and trans-fusion records of 1 00 cancer patients who required exten-sive platelet support revealed that 27 of 1 00 patients exhibited positive HLA antibody tests; only 13 remained positive on repetitive examination, while 88 % of aplastic anemia patients so tested were positive. Sixty-five patients with leukemia, 1 6 with Ewing’s sarcoma, and 19 with recurrent Undifferentiated Lymphoma were studied. Each patient received at least 10 U of platelets (mean of 72). HLA antibodies were detected in 31 % (20/65) of the leukemias, 12 % (2/16) of the Ewing’s. and 26 % (5/19) of the Lymphoma patients. Fourteen of the 27 patients who developed antibodies became antibody negative again C H EMOTH ERAPEUTIC agents used in cancer treatment have been shown to cause at leas
-
of Transfusion-Related Alloimmunization in Intensively
2016Co-Authors: Thomas V. Holohan, Paul I. Terasaki, Albert B. DeisserothAbstract:A retrospective review of HIA antibody testing and transfusion records of 1 00 cancer patients who required extensive platelet support revealed that 27 of 1 00 patients exhibited positive HLA antibody tests; only 13 remained positive on repetitive examination, while 88% of aplastic anemia patients so tested were positive. Sixty-five patients with leukemia, 1 6 with Ewing’s sarcoma, and 19 with recurrent Undifferentiated Lymphoma were studied. Each patient received at least 10 U of platelets (mean of 72). HLA antibodies were detected in 31 % (20/65) of the leukemias, 12% (2/16) of the Ewing’s. and 26% (5/19) of the Lymphoma patients. Fourteen of the 27 patients who developed antibodies became antibody negative again
